Compare CSGP & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSGP | NBIX |
|---|---|---|
| Founded | 1987 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 13.2B |
| IPO Year | 1998 | 1996 |
| Metric | CSGP | NBIX |
|---|---|---|
| Price | $30.46 | $164.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 22 |
| Target Price | $60.57 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 7.6M | 1.3M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 0.14 | ★ 3.30 |
| Revenue | ★ $965,230,000.00 | $161,626,000.00 |
| Revenue This Year | $19.71 | $24.73 |
| Revenue Next Year | $12.40 | $13.14 |
| P/E Ratio | $211.29 | ★ $48.43 |
| Revenue Growth | 15.23 | ★ 977.51 |
| 52 Week Low | $25.89 | $122.14 |
| 52 Week High | $94.93 | $186.12 |
| Indicator | CSGP | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 37.84 |
| Support Level | $28.18 | $153.96 |
| Resistance Level | $31.20 | $160.08 |
| Average True Range (ATR) | 1.44 | 6.51 |
| MACD | 0.24 | -2.47 |
| Stochastic Oscillator | 66.95 | 4.87 |
CoStar Group is a global provider of proprietary information, analytics, and online marketplaces serving both commercial and residential real estate. The firm operates through a diverse portfolio of brands, including CoStar Suite for commercial real estate research, LoopNet for commercial listings, Apartments.com for multifamily rentals, and Homes.com for residential brokerage. It primarily sells high-margin software-as-a-service subscriptions that provide institutional clients with forensic property data and premium advertising visibility. With operations across North America, Europe, and Asia-Pacific, CoStar maintains the industry's most comprehensive centralized real estate database, functioning as a critical information utility for brokers, lenders, and owners worldwide.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.